Results 91 to 100 of about 84,209 (281)
Clinical Pharmacology &Therapeutics, EarlyView.As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Multimorbidity is increasingly prevalent in lower‐ and middle‐income countries. Health‐related quality of life (HRQOL) has been inversely associated with multimorbidity but is understudied in lower‐ and middle‐income countries.
Shalom Sabwa +12 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Priya Jayachandran +13 more
wiley +1 more source
Rheumatic diseases and multimorbidity
Terapevticheskii arkhiv, 2015 In the past decade, investigators' undeniable and justified interest has not been fading in comorbidities in the presence of rheumatic diseases. The terms "comorbidity" and "multimorbidity" are frequently and not always consciously used as interinterchangeable, confusing the terminology and accordingly the elaboration of strategies for further ...
E L Nasonov, A V Gordeev, E A Galushko
openaire +3 more sources
The contribution of musculoskeletal disorders in multimorbidity: Implications for practice and policy [PDF]
, 2017 People frequently live for many years with multiple chronic conditions (multimorbidity) that impair health outcomes and are expensive to manage. Multimorbidity has been shown to reduce quality of life and increase mortality.
Agoritsas +101 more
core +1 more source
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang +7 more
wiley +1 more source
Respiratory ResearchIdiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with chronic progressive fibrosis of unknown etiology; it is characterized by persistent fibrosis of the lungs accompanied by irreversible lung function decline and high mortality rates.
Yuanyuan Zhang +4 more
doaj +1 more source
Multimorbidity in rheumatic conditions [PDF]
Wiener klinische Wochenschrift, 2016 In recent years, multimorbidity in rheumatic conditions has gained increasing attention. Rheumatologist care for an aging patient population with multiple diseases, therefore multimorbidity is the rule, not the exception. Owing to the high prevalence and the potential interaction of coexisting diseases, multimorbidity needs to be taken into account ...
openaire +2 more sources
Development and validation of the Multimorbidity Treatment Burden Questionnaire (MTBQ) [PDF]
, 2018 OBJECTIVE: To develop and validate a new scale to assess treatment burden (the effort of looking after one's health) for patients with multimorbidity. DESIGN: Mixed-methods. SETTING: UK primary care.
Chaplin, Katherine +5 more
core +3 more sources